{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:29:35Z","timestamp":1791606575879,"version":"4.3.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11934-024-01250-4","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T02:15:48Z","timestamp":1736129748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of Lower Urinary Tract Symptoms during the Treatment for Non-Muscle Invasive Bladder Cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Benjamin","family":"Seiden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Ajay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Pietzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"issue":"1","key":"1250_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763. Epub 2023\/01\/13. PubMed PMID: 36633525.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1250_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder Cancer: AUA\/SUO Guideline. J Urol. 2016;196(4):1021\u20139. https:\/\/doi.org\/10.1016\/j.juro.2016.06.049. Epub 2016\/06\/19.","journal-title":"J Urol"},{"issue":"2","key":"1250_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","volume":"25","author":"HA Al","year":"2023","unstructured":"Al HA, Awamlh B, Chang SS. Novel therapies for high-risk non-muscle invasive bladder Cancer. Curr Oncol Rep. 2023;25(2):83\u201391. https:\/\/doi.org\/10.1007\/s11912-022-01350-9. Epub 2022\/12\/27.","journal-title":"Curr Oncol Rep"},{"key":"1250_CR4","doi-asserted-by":"publisher","first-page":"175024","DOI":"10.1016\/j.ejphar.2022.175024","volume":"926","author":"Y Li","year":"2022","unstructured":"Li Y, Youssef SF, Buanz AB. Intravesical combination therapies for non-muscle invasive bladder cancer: recent advances and future directions. Eur J Pharmacol. 2022;926:175024. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175024. Epub 2022\/05\/18.","journal-title":"Eur J Pharmacol"},{"key":"1250_CR5","unstructured":"National Institude of Health. (2024, January 1). Treatment Bladder Cancer NIH. Progressreport.Cancer.gov. Retrieved February 1, 2024, from https:\/\/progressreport.cancer.gov\/treatment\/bladder_cancer#:~:text=In%202019%2C%2035.5%25%20of%20patients,invasive%20disease%20received%20intravesical%20therapy"},{"issue":"4","key":"1250_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.euf.2018.09.009","volume":"4","author":"J Mathes","year":"2018","unstructured":"Mathes J, Todenh\u00f6fer T. Managing toxicity of Intravesical Therapy. Eur Urol Focus. 2018;4(4):464\u20137. https:\/\/doi.org\/10.1016\/j.euf.2018.09.009. Epub 2018\/11\/27.","journal-title":"Eur Urol Focus"},{"issue":"2","key":"1250_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ucl.2013.01.005","volume":"40","author":"JG Griffin","year":"2013","unstructured":"Griffin JG, Holzbeierlein J. Side effects of perioperative intravesical treatment and treatment strategies for these side effects. Urol Clin North Am. 2013;40(2):197\u2013210. https:\/\/doi.org\/10.1016\/j.ucl.2013.01.005. Epub 2013\/04\/02.","journal-title":"Urol Clin North Am"},{"issue":"6","key":"1250_CR8","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/s0022-5347(06)00264-3","volume":"175","author":"MP Koya","year":"2006","unstructured":"Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol. 2006;175(6):2004\u201310. https:\/\/doi.org\/10.1016\/s0022-5347(06)00264-3. Epub 2006\/05\/16.","journal-title":"J Urol"},{"issue":"1","key":"1250_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"M Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65(1):69\u201376. https:\/\/doi.org\/10.1016\/j.eururo.2013.07.021. Epub 2013\/08\/06.","journal-title":"Eur Urol"},{"key":"1250_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.urology.2021.04.062","volume":"156","author":"JM Kuperus","year":"2021","unstructured":"Kuperus JM, Busman RD, Kuipers SK, Broekhuizen HT, Noyes SL, Brede CM, et al. Comparison of Side effects and Tolerability between Intravesical Bacillus Calmette-Guerin, reduced-dose BCG and gemcitabine for non-muscle invasive bladder Cancer. Urology. 2021;156:191\u20138. https:\/\/doi.org\/10.1016\/j.urology.2021.04.062. Epub 2021\/07\/05.","journal-title":"Urology"},{"issue":"4","key":"1250_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4103\/ua.Ua_115_17","volume":"9","author":"MM Alhogbani","year":"2017","unstructured":"Alhogbani MM, Picard JA, Fassi-Fehri MH, Badet JL, Colombel CM. Prognostic impact of Bacillus Calmette-Gu\u00e9rin interruption at the time of induction and consolidation. Urol Ann. 2017;9(4):315\u201320. https:\/\/doi.org\/10.4103\/ua.Ua_115_17. PubMed PMID: 29118530; PubMed Central PMCID: PMCPMC5656953. Epub 2017\/11\/10.","journal-title":"Urol Ann"},{"issue":"6","key":"1250_CR12","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.urology.2008.12.039","volume":"73","author":"T Takeda","year":"2009","unstructured":"Takeda T, Kikuchi E, Yuge K, Matsumoto K, Miyajima A, Nakagawa K, et al. Discontinuance of bacille Calmette-Gu\u00e9rin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence. Urology. 2009;73(6):1318\u201322. https:\/\/doi.org\/10.1016\/j.urology.2008.12.039. Epub 2009\/02\/24.","journal-title":"Urology"},{"issue":"2","key":"1250_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10552-019-1130-8","volume":"30","author":"ML Kwan","year":"2019","unstructured":"Kwan ML, Kushi LH, Danforth KN, Roh JM, Ergas IJ, Lee VS, et al. The Be-well Study: a prospective cohort study of lifestyle and genetic factors to reduce the risk of recurrence and progression of non-muscle-invasive bladder cancer. Cancer Causes Control. 2019;30(2):187\u201393. https:\/\/doi.org\/10.1007\/s10552-019-1130-8. Epub 2019\/01\/19.","journal-title":"Cancer Causes Control"},{"issue":"2","key":"1250_CR14","first-page":"8198","volume":"23","author":"JR Gregg","year":"2016","unstructured":"Gregg JR, McCormick B, Wang L, Cohen P, Sun D, Penson DF, et al. Short term complications from transurethral resection of bladder tumor. Can J Urol. 2016;23(2):8198\u2013203. Epub 2016\/04\/18. PubMed PMID: 27085823.","journal-title":"Can J Urol"},{"issue":"8","key":"1250_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.urolonc.2015.05.011","volume":"33","author":"RS Matulewicz","year":"2015","unstructured":"Matulewicz RS, Sharma V, McGuire BB, Oberlin DT, Perry KT, Nadler RB. The effect of surgical duration of transurethral resection of bladder tumors on postoperative complications: an analysis of ACS NSQIP data. Urol Oncol. 2015;33(8):338. https:\/\/doi.org\/10.1016\/j.urolonc.2015.05.011. e19-24. Epub 2015\/06\/15.","journal-title":"Urol Oncol"},{"key":"1250_CR16","doi-asserted-by":"publisher","unstructured":"Strother M, Barlotta R, Uzzo R, Bloom E, Jazayeri SB, Bigalli AC, et al.e1-.e10. Urol Oncol. 2024;42(4):117. https:\/\/doi.org\/10.1016\/j.urolonc.2023.12.007. PubMed PMID: 38369443. Symptomatic and functional recovery after transurethral resection of bladder tumor: Data from ecological momentary symptom assessmentEpub 2024\/02\/19.","DOI":"10.1016\/j.urolonc.2023.12.007"},{"issue":"1","key":"1250_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.urology.2014.02.034","volume":"84","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Cao Z, Xu C, Wang H, Zhang C, Pan A, et al. Solifenacin is able to improve the irritative symptoms after transurethral resection of bladder tumors. Urology. 2014;84(1):117\u201321. https:\/\/doi.org\/10.1016\/j.urology.2014.02.034. Epub 2014\/05\/03.","journal-title":"Urology"},{"issue":"3","key":"1250_CR18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.juro.2009.05.023","volume":"182","author":"N Lumen","year":"2009","unstructured":"Lumen N, Hoebeke P, Willemsen P, De Troyer B, Pieters R, Oosterlinck W. Etiology of urethral stricture disease in the 21st century. J Urol. 2009;182(3):983\u20137. https:\/\/doi.org\/10.1016\/j.juro.2009.05.023. Epub 2009\/07\/21.","journal-title":"J Urol"},{"issue":"8","key":"1250_CR19","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1089\/end.2009.0575","volume":"24","author":"DP Michielsen","year":"2010","unstructured":"Michielsen DP, Coomans D. Urethral strictures and bipolar transurethral resection in saline of the prostate: fact or fiction? J Endourol. 2010;24(8):1333\u20137. https:\/\/doi.org\/10.1089\/end.2009.0575. Epub 2010\/06\/30.","journal-title":"J Endourol"},{"issue":"2","key":"1250_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3909\/riu0685","volume":"18","author":"ML Chen","year":"2016","unstructured":"Chen ML, Correa AF, Santucci RA. Urethral strictures and stenoses caused by prostate therapy. Rev Urol. 2016;18(2):90\u2013102. https:\/\/doi.org\/10.3909\/riu0685. Epub 2016\/09\/08.","journal-title":"Rev Urol"},{"issue":"2","key":"1250_CR21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1590\/s1677-5538.Ibju.2018.0068","volume":"45","author":"A Lunney","year":"2019","unstructured":"Lunney A, Haynes A, Sharma P. Moderate or severe LUTS is associated with increased recurrence of non - muscle - invasive urothelial carcinoma of the bladder. Int Braz J Urol. 2019;45(2):306\u201314. https:\/\/doi.org\/10.1590\/s1677-5538.Ibju.2018.0068. PubMed PMID: 30325609; PubMed Central PMCID: PMCPMC6541143. Epub 2018\/10\/17.","journal-title":"Int Braz J Urol"},{"issue":"18","key":"1250_CR22","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2018.4657","volume":"319","author":"EM Messing","year":"2018","unstructured":"Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP Jr., et al. Effect of Intravesical Instillation of Gemcitabine vs saline immediately following resection of suspected low-Grade non-muscle-invasive bladder Cancer on Tumor recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018;319(18):1880\u20138. https:\/\/doi.org\/10.1001\/jama.2018.4657. Epub 2018\/05\/26.","journal-title":"JAMA"},{"issue":"2","key":"1250_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","volume":"73","author":"J Bosschieter","year":"2018","unstructured":"Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, Witte B, Newling D, et al. Value of an Immediate Intravesical Instillation of Mitomycin C in patients with non-muscle-invasive bladder Cancer: a prospective Multicentre Randomised Study in 2243 patients. Eur Urol. 2018;73(2):226\u201332. https:\/\/doi.org\/10.1016\/j.eururo.2017.06.038. Epub 2017\/07\/15.","journal-title":"Eur Urol"},{"key":"1250_CR24","doi-asserted-by":"publisher","unstructured":"Carrion DM, G\u00f3mez Rivas J, Ballesteros Ruiz C, Alvarez-Maestro M, Aguilera Baz\u00e1n A, Mart\u00ednez-Pi\u00f1eiro L, Precave. Immediate neoadjuvant instillation of chemotherapy for the prevention of non-muscle invasive bladder carcinoma recurrence: A prospective randomized clinical trial protocol. Int J Surg Protoc. 2020;24:21\u2013\u20096. Epub 2020\/11\/17. https:\/\/doi.org\/10.1016\/j.isjp.2020.10.001. PubMed PMID: 33195885; PubMed Central PMCID: PMCPMC7644741.","DOI":"10.1016\/j.isjp.2020.10.001"},{"issue":"3","key":"1250_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/bf00571847","volume":"22","author":"MJ Stassar","year":"1994","unstructured":"Stassar MJ, Vegt PD, Steerenberg PA, van der Meijden AP, Meiring HD, Dessens-Kroon M, et al. Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer. Urol Res. 1994;22(3):177\u201384. https:\/\/doi.org\/10.1007\/bf00571847. Epub 1994\/01\/01.","journal-title":"Urol Res"},{"issue":"4","key":"1250_CR26","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/S0022-5347(01)64936-X","volume":"157","author":"PD Vegt","year":"1997","unstructured":"Vegt PD, van der Meijden AP, Sylvester R, Brausi M, H\u00f6ltl W, de Balincourt C. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol. 1997;157(4):1246\u20139. Epub 1997\/04\/01. PubMed PMID: 9120912.","journal-title":"J Urol"},{"issue":"2","key":"1250_CR27","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/s0022-5347(05)64751-9","volume":"168","author":"C Durek","year":"2002","unstructured":"Durek C, Jurczok A, Werner H, Jocham D, Bohle A. Optimal treatment of systemic bacillus Calmette-Gu\u00e9rin infection: investigations in an animal model. J Urol. 2002;168(2):826\u201331. https:\/\/doi.org\/10.1016\/s0022-5347(05)64751-9. Epub 2002\/07\/20.","journal-title":"J Urol"},{"issue":"3","key":"1250_CR28","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","volume":"176","author":"M Colombel","year":"2006","unstructured":"Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176(3):935\u20139. https:\/\/doi.org\/10.1016\/j.juro.2006.04.104. Epub 2006\/08\/08.","journal-title":"J Urol"},{"issue":"6","key":"1250_CR29","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.euf.2022.06.002","volume":"8","author":"K Numakura","year":"2022","unstructured":"Numakura K, Kobayashi M, Ishida T, Okane K, Suzuki K, Shimoda N, et al. Effect of levofloxacin on the efficacy and adverse events in intravesical Bacillus Calmette-Guerin treatment for bladder Cancer: results of a Randomized, prospective, Multicenter Study. Eur Urol Focus. 2022;8(6):1666\u201372. https:\/\/doi.org\/10.1016\/j.euf.2022.06.002. Epub 2022\/06\/19.","journal-title":"Eur Urol Focus"},{"issue":"4","key":"1250_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2174\/0929867013373435","volume":"8","author":"A De Sarro","year":"2001","unstructured":"De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr Med Chem. 2001;8(4):371\u201384. Epub 2001\/02\/15. https:\/\/doi.org\/10.2174\/0929867013373435. PubMed PMID: 11172695.","journal-title":"Curr Med Chem"},{"issue":"7662","key":"1250_CR31","doi-asserted-by":"publisher","first-page":"a816","DOI":"10.1136\/bmj.a816","volume":"337","author":"JH Tanne","year":"2008","unstructured":"Tanne JH. FDA adds black box warning label to fluoroquinolone antibiotics. BMJ. 2008;337(7662):a816. https:\/\/doi.org\/10.1136\/bmj.a816. Epub 2008\/07\/18.","journal-title":"BMJ"},{"key":"1250_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1471-2490-14-64","volume":"14","author":"L Topazio","year":"2014","unstructured":"Topazio L, Miano R, Maurelli V, Gaziev G, Gacci M, Iacovelli V, et al. Could hyaluronic acid (HA) reduce Bacillus Calmette-Gu\u00e9rin (BCG) local side effects? Results of a pilot study. BMC Urol. 2014;14:64. https:\/\/doi.org\/10.1186\/1471-2490-14-64. Epub 2014\/08\/16.","journal-title":"BMC Urol"},{"issue":"1","key":"1250_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4081\/aiua.2018.1.11","volume":"90","author":"V Imperatore","year":"2018","unstructured":"Imperatore V, Creta M, Di Meo S, Buonopane R, Longo N, Fusco F, et al. Intravesical administration of combined hyaluronic acid and chondroitin sulfate can improve symptoms in patients with refractory bacillus Calmette-Guerin-induced chemical cystitis: preliminary experience with one-year follow-up. Arch Ital Urol Androl. 2018;90(1):11\u20134. PubMed PMID: 29633792.","journal-title":"Arch Ital Urol Androl"},{"issue":"4","key":"1250_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11255-015-0940-1","volume":"47","author":"W Huang","year":"2015","unstructured":"Huang W, Wang F, Wu C, Hu W. Efficacy and safety of pirarubicin combined with hyaluronic acid for non-muscle invasive bladder cancer after transurethral resection: a prospective, randomized study. Int Urol Nephrol. 2015;47(4):631\u20136. https:\/\/doi.org\/10.1007\/s11255-015-0940-1. Epub 2015\/03\/13.","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"1250_CR35","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/bju.13489","volume":"118","author":"S Yadav","year":"2016","unstructured":"Yadav S, Tomar V, Yadav SS, Priyadarshi S, Banerjee I. Role of oral pentosan polysulphate in the reduction of local side effects of BCG therapy in patients with non-muscle-invasive bladder cancer: a pilot study. BJU Int. 2016;118(5):758\u201362. https:\/\/doi.org\/10.1111\/bju.13489. Epub 2016\/10\/19.","journal-title":"BJU Int"},{"issue":"5","key":"1250_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.4111\/icu.20220179","volume":"63","author":"HY Lee","year":"2022","unstructured":"Lee HY, Jung SI, Lim DG, Chung HS, Hwang EC, Kwon DD. Role of oral pentosan polysulfate in Bacillus Calmette-Gu\u00e9rin therapy in patients with non-muscle-invasive bladder cancer. Investig Clin Urol. 2022;63(5):539\u201345. https:\/\/doi.org\/10.4111\/icu.20220179. Epub 2022\/09\/07.","journal-title":"Investig Clin Urol"},{"issue":"12","key":"1250_CR37","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1158\/2326-6066.Cir-21-0285","volume":"9","author":"N Ji","year":"2021","unstructured":"Ji N, Mukherjee N, Shu ZJ, Reyes RM, Meeks JJ, McConkey DJ, et al. \u03b3\u03b4 T cells support Antigen-Specific \u03b1\u03b2 T cell-mediated antitumor responses during BCG treatment for bladder Cancer. Cancer Immunol Res. 2021;9(12):1491\u2013503. https:\/\/doi.org\/10.1158\/2326-6066.Cir-21-0285. Epub 2021\/10\/06.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"1250_CR38","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/nm1295-1297","volume":"1","author":"JI Mayordomo","year":"1995","unstructured":"Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1(12):1297\u2013302. https:\/\/doi.org\/10.1038\/nm1295-1297. Epub 1995\/12\/01.","journal-title":"Nat Med"},{"issue":"3","key":"1250_CR39","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/s0022-5347(17)35678-1","volume":"150","author":"TL Ratliff","year":"1993","unstructured":"Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993;150(3):1018\u201323. https:\/\/doi.org\/10.1016\/s0022-5347(17)35678-1. Epub 1993\/09\/01.","journal-title":"J Urol"},{"key":"1250_CR40","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.2147\/opth.S340041","volume":"15","author":"EH Leung","year":"2021","unstructured":"Leung EH, Sharma S, Levie-Sprick A, Lee GD, Cho H, Mukkamala K. Pentosan Polysulfate Sodium-Associated Pigmentary Retinopathy: risk factors and Fundus findings. Clin Ophthalmol. 2021;15:4809\u201316. https:\/\/doi.org\/10.2147\/opth.S340041. Epub 2022\/01\/08.","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"1250_CR41","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","volume":"7","author":"JA Witjes","year":"2008","unstructured":"Witjes JA, Palou J, Soloway M, Lamm D, Brausi M, Spermon JR, et al. Clinical practice recommendations for the Prevention and Management of Intravesical Therapy\u2013Associated adverse events. Eur Urol Supplements. 2008;7(10):667\u201374. https:\/\/doi.org\/10.1016\/j.eursup.2008.08.001","journal-title":"Eur Urol Supplements"},{"key":"1250_CR42","doi-asserted-by":"publisher","unstructured":"Kamali K, Nikbakht J, Ayubi E, Nabizadeh M, Sarhadi S. Comparison of the Efficacy of Oxybutynin, Phenazopyridine, Celecoxib, and Placebo in the Treatment of Urinary Tract Symptoms after BCG Therapy in Patients with Bladder Tumors. Urol J. 2020;18(4):439\u2013\u200944. Epub 2020\/09\/28. https:\/\/doi.org\/10.22037\/uj.v16i7.5947. PubMed PMID: 32981029. A prospective, randomized, triple-blind, placebo-controlled trial trials comparing common oral agents prescribed for LUTS during intravesical therapy. Oxybutynin in this trial did not demonstrate efficacy in LUTS improvement in this clincial setting. Phenazopyridine did improve irritative LUTS.","DOI":"10.22037\/uj.v16i7.5947"},{"issue":"4","key":"1250_CR43","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.juro.2012.10.070","volume":"189","author":"MH Johnson","year":"2013","unstructured":"Johnson MH, Nepple KG, Peck V, Trinkaus K, Klim A, Sandhu GS, et al. Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Gu\u00e9rin treatment. J Urol. 2013;189(4):1268\u201374. https:\/\/doi.org\/10.1016\/j.juro.2012.10.070. Epub 2012\/11\/06.","journal-title":"J Urol"},{"issue":"10","key":"1250_CR44","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/14740338.2020.1817377","volume":"19","author":"G Araklitis","year":"2020","unstructured":"Araklitis G, Robinson D. The cognitive safety of antimuscarinics in the treatment of overactive bladder. Expert Opin Drug Saf. 2020;19(10):1303\u201313. PubMed PMID: 32857638.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1250_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/1756287215599695","volume":"7","author":"V Pagliarulo","year":"2015","unstructured":"Pagliarulo V, Ancona P, Martines I, Spadavecchia R, Di Stasi S, Alba S, et al. Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study. Ther Adv Urol. 2015;7(6):303\u201311. PubMed PMID: 26622316; PubMed Central PMCID: PMCPMC4647141.","journal-title":"Ther Adv Urol"},{"issue":"4","key":"1250_CR46","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.eururo.2018.09.020","volume":"75","author":"JD Kelly","year":"2019","unstructured":"Kelly JD, Tan WS, Porta N, Mostafid H, Huddart R, Protheroe A, et al. BOXIT-A Randomised Phase III Placebo-controlled Trial evaluating the addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the bladder (CRUK\/07\/004). Eur Urol. 2019;75(4):593\u2013601. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.020. Epub 2018\/10\/04.","journal-title":"Eur Urol"},{"issue":"6","key":"1250_CR47","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.urolonc.2023.04.003","volume":"41","author":"T Kawada","year":"2023","unstructured":"Kawada T, Yanagisawa T, Bekku K, Laukhtina E, von Deimling M, Chlosta M, et al. The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: a network meta-analysis. Urol Oncol. 2023;41(6):261\u201373. https:\/\/doi.org\/10.1016\/j.urolonc.2023.04.003. Epub 2023\/05\/04.","journal-title":"Urol Oncol"},{"key":"1250_CR48","doi-asserted-by":"publisher","unstructured":"Choi SY, Ha MS, Kim JH, Chi BH, Kim JW, Chang IH et al. Low-dose versus standard-dose bacille Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials. Investig Clin Urol. 2022;63(2):140\u2013\u200950. Epub 2022\/03\/05. https:\/\/doi.org\/10.4111\/icu.20210340. PubMed PMID: 35244987; PubMed Central PMCID: PMCPMC8902423. Meta-analysis with over 1,000 patients demonstrating that lower dose BCG patients had significant reduction in local side effects including LUTS compared to full dose BCG patients. Increased risk of tumor reccurence but no demonstrated difference in bladder cancer progression or survival.","DOI":"10.4111\/icu.20210340"},{"issue":"1","key":"1250_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/0974-7796.106873","volume":"5","author":"T Inamoto","year":"2013","unstructured":"Inamoto T, Ubai T, Nishida T, Fujisue Y, Katsuoka Y, Azuma H. Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Gu\u00e9rin prophylaxis in nonmuscle invasive bladder cancer: results of a randomized prospective comparison. Urol Ann. 2013;5(1):7\u201312. https:\/\/doi.org\/10.4103\/0974-7796.106873. Epub 2013\/05\/11.","journal-title":"Urol Ann"},{"issue":"5","key":"1250_CR50","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/s0022-5347(17","volume":"147","author":"A Morales","year":"1992","unstructured":"Morales A, Nickel JC, Wilson JW. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol. 1992;147(5):1256\u20138. https:\/\/doi.org\/10.1016\/s0022-5347(17. Epub 1992\/05\/01.","journal-title":"J Urol"},{"issue":"1","key":"1250_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/bf02550276","volume":"30","author":"F Yal\u00e7inkaya","year":"1998","unstructured":"Yal\u00e7inkaya F, Kami\u015f L, Ozteke O, G\u00fcnl\u00fcsoy B, Yigitba\u015fi O, Unal S. Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer. Int Urol Nephrol. 1998;30(1):41\u20134. https:\/\/doi.org\/10.1007\/bf02550276. Epub 1998\/05\/06.","journal-title":"Int Urol Nephrol"},{"issue":"4 Pt 1","key":"1250_CR52","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","volume":"174","author":"JA Mart\u00ednez-Pi\u00f1eiro","year":"2005","unstructured":"Mart\u00ednez-Pi\u00f1eiro JA, Mart\u00ednez-Pi\u00f1eiro L, Solsona E, Rodr\u00edguez RH, G\u00f3mez JM, Mart\u00edn MG, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 2005;174(4 Pt 1):1242\u20137. https:\/\/doi.org\/10.1097\/01.ju.0000173919.28835.aa. Epub 2005\/09\/08.","journal-title":"J Urol"},{"key":"1250_CR53","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Pi\u00f1eiro JA, Flores N, Isorna S, Solsona E, Sebasti\u00e1n JL, Pertusa C et al. Long-term follow-up of a randomized prospective trial comparing a standard 81\u00a0mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27\u00a0mg in superficial bladder cancer. BJU Int. 2002;89(7):671\u2013\u200980. Epub 2002\/04\/23. https:\/\/doi.org\/10.1046\/j.1464-410x.2002.02722.x. PubMed PMID: 11966623.","DOI":"10.1046\/j.1464-410x.2002.02722.x"},{"key":"1250_CR54","doi-asserted-by":"publisher","unstructured":"Vijjan V, Mandhani A, Kapoor R, Dubey D, Srivastava A, Ansari M, et al. A randomized trial comparing low dose (40 or 80\u00a0mg) with standard dose (120\u00a0mg) of bacillus Calmette-Guerin for superficial bladder cancer. Indian J Urol. 2006;22. https:\/\/doi.org\/10.4103\/0970-1591.29117","DOI":"10.4103\/0970-1591.29117"},{"issue":"12","key":"1250_CR55","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2217\/imt-2022-0309","volume":"15","author":"T Kawada","year":"2023","unstructured":"Kawada T, Yanagisawa T, Bekku K, Laukhtina E, Deimling MV, Majdoub M, et al. Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis. Immunotherapy. 2023;15(12):933\u201343. https:\/\/doi.org\/10.2217\/imt-2022-0309. Epub 2023\/07\/06.","journal-title":"Immunotherapy"},{"issue":"6","key":"1250_CR56","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.urology.2007.07.017","volume":"70","author":"MS Agrawal","year":"2007","unstructured":"Agrawal MS, Agrawal M, Bansal S, Agarwal M, Lavania P, Goyal J. The safety and efficacy of different doses of bacillus Calmette Gu\u00e9rin in superficial bladder transitional cell carcinoma. Urology. 2007;70(6):1075\u20138. https:\/\/doi.org\/10.1016\/j.urology.2007.07.017. Epub 2007\/12\/26.","journal-title":"Urology"},{"issue":"5","key":"1250_CR57","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.urolonc.2020.01.002","volume":"38","author":"R Sood","year":"2020","unstructured":"Sood R, Sharma H, Sharma B, Parekh S, Pujari P, Shewale S. A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer. Urol Oncol. 2020;38(5):433\u20139. https:\/\/doi.org\/10.1016\/j.urolonc.2020.01.002. Epub 2020\/02\/11.","journal-title":"Urol Oncol"},{"issue":"5","key":"1250_CR58","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"A Ojea","year":"2007","unstructured":"Ojea A, Nogueira JL, Solsona E, Flores N, G\u00f3mez JM, Molina JR, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27\u00a0mg) versus very low-dose bacillus Calmette-Guerin (13.5\u00a0mg) versus mitomycin C. Eur Urol. 2007;52(5):1398\u2013406. https:\/\/doi.org\/10.1016\/j.eururo.2007.04.062. Epub 2007\/05\/09.","journal-title":"Eur Urol"},{"issue":"3","key":"1250_CR59","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462\u201372. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.039. Epub 2012\/11\/13.","journal-title":"Eur Urol"},{"issue":"4","key":"1250_CR60","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.aju.2015.07.002","volume":"13","author":"W Kandeel","year":"2015","unstructured":"Kandeel W, Abdelal A, Elmohamady BN, Sebaey A, Elshaaer W, Elbarky E, et al. A comparative study between full-dose and half-dose intravesical immune bacille Calmette-Gu\u00e9rin injection in the management of superficial bladder cancer. Arab J Urol. 2015;13(4):233\u20137. PubMed PMID: 26609439; PubMed Central PMCID: PMCPMC4656796.","journal-title":"Arab J Urol"},{"issue":"2","key":"1250_CR61","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/14656566.2024.2310073","volume":"25","author":"M Abou Chakra","year":"2024","unstructured":"Abou Chakra M, Packiam VT, Duquesne I, Peyromaure M, McElree IM, O\u2019Donnell MA. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now? Expert Opin Pharmacother. 2024;25(2):203\u201314. https:\/\/doi.org\/10.1080\/14656566.2024.2310073. Epub 2024\/01\/24.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1250_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ucl.2019.09.010","volume":"47","author":"NA Brooks","year":"2020","unstructured":"Brooks NA, O\u2019Donnell MA. Combination Intravesical Therapy. Urol Clin North Am. 2020;47(1):83\u201391. https:\/\/doi.org\/10.1016\/j.ucl.2019.09.010. Epub 2019\/11\/24.","journal-title":"Urol Clin North Am"},{"issue":"6suppl","key":"1250_CR63","doi-asserted-by":"publisher","first-page":"TPS579","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS579","volume":"41","author":"C Gaffney","year":"2023","unstructured":"Gaffney C, Dsouza N, Hernandez C, McCarter M, Moran P, Stasi K, et al. A phase II trial of intravesical chemoimmunotherapy with gemcitabine and bacillus Calmette-Gu\u00e9rin (BCG) for patients with BCG-exposed, high-grade, non-muscle\u2013invasive bladder cancer. J Clin Oncol. 2023;41(6suppl):TPS579\u2013TPS. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.TPS579","journal-title":"J Clin Oncol"},{"issue":"1","key":"1250_CR64","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","volume":"18","author":"M Racioppi","year":"2018","unstructured":"Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk BCG failure non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer. 2018;18(1):1224. https:\/\/doi.org\/10.1186\/s12885-018-5134-7. Epub 2018\/12\/14.","journal-title":"BMC Cancer"},{"issue":"5","key":"1250_CR65","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/JU.0000000000003195","volume":"209","author":"MD Tyson","year":"2023","unstructured":"Tyson MD, Morris D, Palou J, Rodriguez O, Mir MC, Dickstein RJ, et al. Safety, Tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder Cancer who refused or were unfit for curative-intent therapy: a phase 1 study. J Urol. 2023;209(5):890\u2013900. https:\/\/doi.org\/10.1097\/JU.0000000000003195","journal-title":"J Urol"},{"issue":"5","key":"1250_CR66","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/ju.0000000000003195","volume":"209","author":"MD Tyson","year":"2023","unstructured":"Tyson MD, Morris D, Palou J, Rodriguez O, Mir MC, Dickstein RJ, et al. Safety, Tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder Cancer who refused or were unfit for curative-intent therapy: a phase 1 study. J Urol. 2023;209(5):890\u2013900. https:\/\/doi.org\/10.1097\/ju.0000000000003195. Epub 2023\/04\/08.","journal-title":"J Urol"},{"key":"1250_CR67","doi-asserted-by":"publisher","first-page":"985288","DOI":"10.3389\/fneur.2022.985288","volume":"13","author":"JJ Lee","year":"2022","unstructured":"Lee JJ, Heo JW, Choi TY, Jun JH, Lee MS, Kim JI. Acupuncture for the treatment of overactive bladder: a systematic review and meta-analysis. Front Neurol. 2022;13:985288. https:\/\/doi.org\/10.3389\/fneur.2022.985288. Epub 2023\/01\/31.","journal-title":"Front Neurol"},{"key":"1250_CR68","doi-asserted-by":"publisher","first-page":"101044","DOI":"10.1016\/j.conctc.2022.101044","volume":"30","author":"SP Psutka","year":"2022","unstructured":"Psutka SP, Veleber S, Siman J, Jannat S, Holt S, Wright JL, et al. Effects of acupuncture to decrease adverse events in patients with high-risk non-muscle invasive bladder cancer receiving induction intravesical BCG therapy: study protocol for a randomized, controlled pilot and feasibility study. Contemp Clin Trials Commun. 2022;30:101044. PubMed PMID: 36561732; PubMed Central PMCID: PMCPMC9763430.","journal-title":"Contemp Clin Trials Commun"},{"key":"1250_CR69","doi-asserted-by":"publisher","unstructured":"Safarpour D, Jabbari B. Botulinum Toxin Treatment for Cancer-Related Disorders: A Systematic Review. Toxins (Basel). 2023;15(12). Epub 2023\/12\/22. https:\/\/doi.org\/10.3390\/toxins15120689. PubMed PMID: 38133193; PubMed Central PMCID: PMCPMC10748363.","DOI":"10.3390\/toxins15120689"},{"key":"1250_CR70","doi-asserted-by":"publisher","unstructured":"Chuang YC, Kim DK, Chiang PH, Chancellor MB. Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis. BJU Int. 2008;102(6):704-6. Epub 2008\/05\/20. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.07740.x. PubMed PMID: 18485037.","DOI":"10.1111\/j.1464-410X.2008.07740.x"},{"issue":"21","key":"1250_CR71","doi-asserted-by":"publisher","first-page":"7534","DOI":"10.1002\/cam4.4278","volume":"10","author":"K Sun","year":"2021","unstructured":"Sun K, Wang D, Wu G, Ma J, Wang T, Wu J, et al. Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors. Cancer Med. 2021;10(21):7534\u201341. https:\/\/doi.org\/10.1002\/cam4.4278. Epub 2021\/09\/22. In Double blind placebo study, mirabegron administered during BCG induction had significant reduction in irritative LUTS demonstrated with bladder diaries.","journal-title":"Cancer Med"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-024-01250-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-024-01250-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-024-01250-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:03:03Z","timestamp":1767985383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-024-01250-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1007\/s11934-024-01250-4","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"25 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors were performed in accordance with all applicable ethical standards including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines.The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Dr. Eugene Pietzak is a section editor for\n                      Current Urology Reports\n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"24"}}